Tislelizumab is BeiGene’s programmed cell death protein 1 (PD-1) checkpoint inhibitor and Anktiva is an interleukin-15 (IL-15) superagonist from ImmunityBio. The trial aims to confirm the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback